Oblenio begins first clinical trial of new therapy for autoimmune diseases

Oblenio begins first clinical trial of new therapy for autoimmune diseases

Oblenio has started a Phase 1a clinical trial of its investigational therapy LBL-051, with the first patients now receiving treatment.

LBL-051 is being developed for autoimmune diseases — conditions in which the immune system mistakenly attacks the body's own healthy cells and tissues. The therapy is primarily intended for patients whose disease does not respond adequately to existing treatments.

The new treatment is designed to target both B cells and plasma cells, which play important roles in the immune system. LBL-051 acts on two biological targets, CD19 and BCMA, with the aim of reducing the abnormal immune activity associated with autoimmune disease.

According to the developers, this dual-targeting approach may provide deeper and longer-lasting control of the immune response and could potentially help some patients achieve sustained remission without continuous medication.

The multicentre study will assess the therapy's safety, tolerability, clinical response and effects on immune cells. LBL-051 is administered by subcutaneous injection.

The therapy remains at an early stage of clinical development, and its effectiveness and safety will be determined through further clinical studies.